Evidence map›Paper›PMID 17169430›Full record

ArticleMolecular immunology2007

Cellular uptake followed by class I MHC presentation of some exogenous peptides contributes to T cell stimulatory capacity.

Susan E Brophy, Lindsay L Jones, Phillip D Holler, David M Kranz

Abstract read
In one paragraph

Article in Molecular immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Promiscuous binding of extracellular peptides to cell surface class I MHC protein.Proceedings of the National Academy of Sciences of the United States of America · 2012
    Article
  4. Article
  5. Characterizing the dynamics of CD4+ T cell priming within a lymph node.Journal of immunology (Baltimore, Md. : 1950) · 2010
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Susan E BrophyDepartment of Biochemistry, University of Illinois, 600 S. Matthews Avenue, Urbana, IL 61801, USA.
Lindsay L Jones
Phillip D Holler
David M Kranz

Funding

Structure, Function &Engineering of Tau Cell ReceptorsR01GM055767 · NIGMS · UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN · PI KRANZ, DAVID M. · 1997 to 2009
$2.4M
NIGMS NIH HHS GM55767NIGMS NIH HHS R01 GM055767
6 · The paper itself

Abstract

The T cell stimulatory activity of peptides is known to be associated with the cell surface stability and lifetime of the peptide-MHC (pepMHC) complex. In this report, soluble high-affinity T cell receptors (TCRs) that are specific for pepMHC complexes recognized by the mouse CD8+ clone 2C were used to monitor the cell surface lifetimes of synthetic agonist peptides. In the 2C system, L(d)-binding peptide p2Ca (LSPFPFDL) has up to 10,000-fold lower activity than peptide QL9 (QLSPFPFDL) even though the 2C TCR binds to p2Ca-L(d) and QL9-L(d) complexes with similar affinities. Unexpectedly, p2Ca-L(d) complexes were found to have a longer cell surface lifetime than QL9-L(d) complexes. However, the strong agonist activity of QL9 correlated with its ability to participate in efficient intracellular delivery followed by cell surface expression of the peptide, resulting in high and persistent surface levels of QL9-L(d). The ability of target cells to take up and present QL9 was observed with TAP-deficient cells and TAP-positive cells, including dendritic cells. The process was brefeldin A-sensitive, indicating a requirement for transport of the pepMHC through the ER and/or golgi. Thus, strong T cell stimulatory activity of some pepMHC complexes can be accomplished not only through long cell surface lifetimes of the ligand, but through a mechanism that leads to delayed presentation of the exogenous antigen after intracellular uptake.

Indexed as

Amino Acid SequenceAnimalsAntigen PresentationBone Marrow CellsBrefeldin ACell Line, TumorDendritic CellsEndoplasmic ReticulumGolgi ApparatusHistocompatibility Antigens Class IHumansLymphocyte ActivationMiceMolecular Sequence DataPeptidesTime FactorsBrefeldin AHistocompatibility Antigens Class IPeptides

Identifiers

PMID17169430
PMCPMC2547883

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.